Decreasing mortality has been seen since the mid-1990s in patients with multiple myeloma due to intensification of frontline therapies. Read More ›

Single-agent belantamab mafodotin shows anti-myeloma activity in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›

Early IONA-MM data show promising real-world evidence of the benefits of isatuximab in patients with relapsed/refractory multiple myeloma. Read More ›

New treatment options are under consideration for consolidation and maintenance therapy after autologous stem-cell transplantation in newly diagnosed patients with multiple myeloma. Read More ›

A single infusion of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma resulted in an overall response rate of 95%. Read More ›

Minimal residual disease assessments are increasingly being used in the clinical trial setting. Read More ›

Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read More ›

Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read More ›

Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read More ›

Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read More ›